Sonoma biotherapeutics round a financing of US $40 million

Editor's note: at present, tens of millions of people suffer from autoimmune diseases, and millions more suffer from some form of degenerative diseases For patients with this kind of disease, the existing treatment can no longer meet their needs of disease control Recently, Sonoma biotherapeutics, a company focusing on the development of autoimmune and degenerative disease regulatory T cell therapy, announced its establishment and completed a round of financing of 40 million US dollars Founded by four pioneers in Treg cell biology and cell therapy, the company is invested by arch venture partners, a well-known venture capital firm Tregs is a natural T cell subpopulation, which can negatively regulate the immune response and maintain the immune balance in vivo by inducing and maintaining the tolerance to autoantigens Tregs can prevent autoimmune diseases by inhibiting excessive immune response in healthy human body Tregs cell therapy can restore the patient's tolerance by stopping the harmful inflammatory reaction in autoimmune diseases (such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis) Tregs cells have a natural ability to control harmful immune responses, making them ideal for the treatment of many diseases In addition, the ability of engineered Tregs cells to target specific pathogenic antigens also reduces the possibility of harmful systemic effects Its role in tissue maintenance and repair provides potential for long-term and effective restorative therapy The company brings together research, development and manufacturing capabilities in cell therapy and genetic engineering, as well as a team of executives, scientists, board members and investors with extensive experience in cell therapy and drug discovery Its co-founder, Professor Jeff bluestone, who was a former CEO of the Parker Institute for cancer immunology, is known for his discovery of a new generation of CTLA-4 targets for cancer immunotherapy In addition, among the other three co founders, Dr Fred Ramsdell and Dr Alexander rudensky jointly discovered Foxp3, a key transcription factor for Treg cell development and function Dr Qizhi Tang, together with Professor Jeff bluestone, applied the therapy to the clinical treatment of type 1 diabetes, lupus and organ transplantation for the first time.